- Home
- ATIF vs LSBPW Comparison
ATIF vs LSBPW Comparison
Compare ATIF & LSBPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATIF
- LSBPW
- Stock Information
- Founded
- ATIF 2015
- LSBPW N/A
- Country
- ATIF United States
- LSBPW China
- Employees
- ATIF N/A
- LSBPW 758
- Industry
- ATIF Professional Services
- LSBPW Biotechnology: Pharmaceutical Preparations
- Sector
- ATIF Consumer Discretionary
- LSBPW Health Care
- Exchange
- ATIF Nasdaq
- LSBPW Nasdaq
- Market Cap
- ATIF 9.8M
- LSBPW N/A
- IPO Year
- ATIF 2019
- LSBPW N/A
- Fundamental
- Price
- ATIF $0.86
- LSBPW $0.07
- Analyst Decision
- ATIF
- LSBPW
- Analyst Count
- ATIF 0
- LSBPW 0
- Target Price
- ATIF N/A
- LSBPW N/A
- AVG Volume (30 Days)
- ATIF 214.7K
- LSBPW N/A
- Earning Date
- ATIF 12-13-2024
- LSBPW N/A
- Dividend Yield
- ATIF N/A
- LSBPW N/A
- EPS Growth
- ATIF N/A
- LSBPW N/A
- EPS
- ATIF N/A
- LSBPW N/A
- Revenue
- ATIF $500,000.00
- LSBPW N/A
- Revenue This Year
- ATIF N/A
- LSBPW N/A
- Revenue Next Year
- ATIF N/A
- LSBPW N/A
- P/E Ratio
- ATIF N/A
- LSBPW N/A
- Revenue Growth
- ATIF N/A
- LSBPW N/A
- 52 Week Low
- ATIF $0.58
- LSBPW N/A
- 52 Week High
- ATIF $1.50
- LSBPW N/A
- Technical
- Relative Strength Index (RSI)
- ATIF 46.75
- LSBPW N/A
- Support Level
- ATIF $0.85
- LSBPW N/A
- Resistance Level
- ATIF $1.50
- LSBPW N/A
- Average True Range (ATR)
- ATIF 0.18
- LSBPW 0.00
- MACD
- ATIF -0.01
- LSBPW 0.00
- Stochastic Oscillator
- ATIF 15.82
- LSBPW 0.00
About ATIF ATIF Holdings Limited
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About LSBPW LakeShore Biopharma Co. Ltd
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.